Merck settles a marketing lawsuit for $5.9 million; CVS plans to create diagnostic apps; a survey shows advertising agencies plan to keep head count steady for the rest of the year
We know it's early days (the smartwatch been available for three days to be exact), but we'd like to know how it is going.
Apple is putting the power of clinical trials in our pockets with ResearchKit.
The small screen makes it a user-friendly medication adherence tool.
The app for the smartwatch includes secure encrypted messaging.
The open-source framework uses the iPhone's apps to gather users' health information.
Phunware's VP Product Evangelist will explore how hospitals can implement a wayfinding and messaging solution, and how they can expect to benefit from it.
FDA draws fine line between health and wellness apps; Colorado gives biosimilar swap law another look; ZMapp is set to start human trials of its Ebola vaccine.
United Healthcare's Baby Blocks app seeks to become all-in-one hub for expectant moms and their babies.
Researchers say the iPad app could help assess vision loss.
The health and lifestyle resource's latest app seeks to provide context for all that biometric data consumers are storing in wearables, wireless scales and glucometers.
The bedside decision-making app includes clinical trial and drug information as well as breaking news.
The maker of an FDA-approved app says its algorithm can use images to assess surgery-related blood loss.
TapTrak seeks to apply behavioral tracking to clinical trials.
The agency issued final guidance on mobile apps, saying it will focus only on a subset that present the greatest risk to patients if they don't work correctly.
FDA is concerned state biosimilar legislation could make consumers uneasy about the category, J&J hands $75 million milestone payment for ibrutinib, Consumer Reports gets into drug apps
Patient use of the professional app prompted the latest iteration, and the foundation behind it is set to launch a media push.
The months-old app seeks to become an all-in-one HCP tool and work on a 3.0 version is already in place.
Medscape asked and doctors shared what they hate about most medical apps, Livestrong merch hits the clearance rack, healthcare reform savings begin to surface, Lilly releases early RA drug trial results
Plan B age limits retained and rejected, Celgene drugs gets expanded indication, Komen cuts back on walks, Apple is policing medical apps, OPDP director's Q&A
Sanofi named Connect & Coach as the winner of its 2013 Data Design Diabetes contest
Actavis buys Warner Chilcott, FDA clears oral insulin for testing, Elan swallows AOP Orphan for $340M
Bayer's prostate cancer drug clears FDA three months early; a House committee is pressing the regulator for employment transparancy; and Ranbaxy takes a multi-million dollar hit over violations
PricewaterhouseCoopers says consumers are talking healthcare, but not about the good stuff; Novartis shuffles 120 Texas jobs; 73% of STD app queries came from men last month; FDA is keeping very busy; and OgilvyCommonhealth hires a consumer head
Roche and Isis pair up for Huntingtons, Vital's prescription vision app gets approved, FDA approval revives maligned morning sickness drug, Gilead sends hep C therapy to regulators and Sanofi's emerging market exposure grabs attention.
Sanofi Pasteur scored a pharma first this past winter by offering "Shazam" technology as a way for viewers to interact with TV commercials for its Fluzone Intradermal influenza vaccine—and to find out where they could get the new shot.
Shire expands its pipeline yet again, AthenaHealth stretches its HCP-patient reach, FDA delays GSK's bird-flu vaccine, Novartis wins approval for cystic fibrosis inhaler
Taking a page from Sanofi, Shire is preparing to launch a developer challenge "to create technology driven solutions that aid individuals with ADHD during the transition from adolescence into adulthood."
GSK, Pfizer and Shionogi's HIV medication to get its day in regulatory court; Philips finds that mobile and health are becoming inseparable.
Nature releases the Antibodypedia's seventh generation, Elsevier adds more board review apps, and how redefining "senior" may not save money in the long run